-
Pluslife Showcases Diagnostic Innovation at WHA78 Side Event: Innovation in Financing and New Technologies to End TB
We remain committed to developing scalable, accessible diagnostic solutions that strengthen TB response efforts in high-burden settings.
넶51 2025-05-23 -
Pluslife at WHA78 Side Event | Contributing to Global Health with China's Diagnostic Innovation
Pluslife participated in the WHA78 side event to share how China’s molecular diagnostic innovation is contributing to improved accessibility and equity in global primary healthcare.
넶87 2025-05-21 -
Pluslife Wins the "2024 Medical Health Corporate Responsibility Model Award," Leading New Breakthroughs in Tuberculosis Control
Pluslife won the "2024 Medical Health Corporate Responsibility Model Award" at the 14th Philanthropy Festival and 2024 ESG Impact Summit, recognizing its outstanding contributions to global tuberculosis control and corporate social responsibility.
넶148 2025-01-16 -
Pluslife Advances Global TB Testing Innovation and Expands Development of Drug-Resistant TB Products
Pluslife is accelerating efforts to provide cost-effective TB diagnostic tools, enhancing accessibility in high-burden areas, and helping to curb TB's spread globally.
넶551 2024-12-04 -
Advancing TB Diagnostics: Pluslife's Commitment to Accessible Solutions
Pluslife’s TB detection product has surpassed the World Health Organization’s (WHO) stringent requirements for 'near POC non-sputum diagnostic' platforms.
넶378 2024-11-25 -
Pluslife Secures Indonesian Import License for Groundbreaking Mycobacterium Tuberculosis Nucleic Acid Test Card
Recently, Pluslife's self-developed rapid molecular diagnostic test card for tuberculosis, utilizing tongue swab samples, was awarded an import medical device license by the Indonesian government. This milestone marks a significant breakthrough following the earlier certification of Pluslife’s sputum sample TB diagnostic technology.
넶364 2024-09-09
